Shaker Spotlight
TAE KIM APPOINTED CEO OF ALLERVIE HEALTH
AllerVie Health has appointed Tae Kim as its new Chief Executive Officer, marking a strategic move to further its mission in allergy and asthma care. Tae Kim, who previously served as Chief Operating Officer, brings extensive experience in healthcare and strategic partnerships, having significantly expanded AllerVie’s clinic network and provider base under his leadership since 2021.
Under Kim’s leadership, AllerVie aims to redefine allergy and asthma care nationally, building on its strong foundation and commitment to patient-centered excellence. His tenure at AllerVie underscores his commitment to enhancing healthcare services through innovative partnerships and strategic growth initiatives. The transition reflects AllerVie’s dedication to continuous innovation and excellence in healthcare delivery, guided by a strategic roadmap to meet evolving patient and physician needs in the allergy and immunology field.
REZO THERAPEUTICS NAMES DR. CRISTIANA GUIDUCCI AS CHIEF SCIENTIFIC OFFICER TO ADVANCE PRECISION THERAPEUTICS
Rezo Therapeutics has appointed Dr. Cristiana Guiducci as its new Chief Scientific Officer, a move aimed at bolstering its capabilities in precision therapeutics. With nearly two decades of experience in oncology and immunology drug discovery, Dr. Guiducci brings a wealth of expertise from her previous roles, including Senior Vice President of Immunology and Oncology Research at Nurix Therapeutics and leadership positions at Dynavax Technologies.
“Cristiana brings deep scientific experience in drug discovery and has important expertise in building foundational research teams, identifying drug candidates and laying the groundwork for clinical advancement,” said Nevan Krogan, Ph.D., president and co-founder of Rezo Therapeutics.
Oxford Biomedica
The gene and cell therapy company has appointed Lucinda Crabtree, Ph.D., as Chief Financial Officer and Board member. Dr. Crabtree brings extensive experience in driving growth and executing strategic initiatives from her previous role as CFO of MorphoSys AG, where she led the finance team through significant milestones including the company’s acquisition by Novartis.
Corewell Health
Corewell Health has undergone a leadership transition as longtime President Dr. Loren Hamel officially retired this past June. Today, the non-profit healthcare company announced that Natalie Baggio, RN, currently Senior Vice President, Chief Operating Officer, and Chief Nursing Executive, will assume the role of regional president for Southwest Michigan. Baggio has been instrumental in healthcare leadership roles at Corewell since 2017, and her deep roots in Southwest Michigan along with her dedication to enhancing patient care and community health makes her perfect for the role.
One2Treat
Dr. Pascal Piedbois assumes a pivotal role at One2Treat, spearheading the development of patient-centric solutions aimed at transforming clinical trial methodologies. With over three decades of clinical development experience spanning academia and industry, including senior positions at AstraZeneca and Bristol Myers Squibb, Dr. Piedbois is poised to address biopharma’s challenge of holistic treatment assessments.
CG Life
Industry veteran Jay Carter has joined CG Life as Executive Vice President, Business Development. Carter has had a four decade long career, including positions at JUICE Pharma world as Executive Vice President and before that over 35 years with AbelsonTaylor, where he led business development and customer engagement functions. Most recently, Carter launched his own consulting firm, Into the Wild Consulting, where he was providing part-time consulting services to CG Life prior to joining the agency full-time.
Mover Alert
Our list of recent hires and promotions in key positions at Pharma, Life Sciences, and Healthcare companies.
Velocity Clinical Research
Mike Zaranek has been appointed Chief Financial Officer (CFO) at Velocity Clinical Research. He will direct the company’s financial goals and accounting, and advise on the Company’s strategic direction. Mike served as CFO at Science 37, where he was instrumental in shaping the financial strategies that supported the company’s leadership in decentralized clinical trials and Nasdaq Global Market debut as a publicly traded company in 2021.
Neurona Therapeutics
Manher (AJ) Joshi, M.D. has been announced as Chief Medical Officer for Neurona Therapeutics. Prior to joining Neurona, AJ served as Atara Biotherapeutics’ Chief Medical Officer and EVP, Head of Clinical Development. There, AJ led the development organization through key milestones across several programs in neurology, oncology, and autoimmune diseases, including multiple IND filings, Ph I-III clinical studies, and securing the first-ever approval for an allogeneic T-cell immunotherapy.
Mission Bio
Roman Haehn has been appointed as Chief Commercial Officer for Mission Bio. With more than 25 years of experience in diagnostics and life sciences research, Roman will lead Mission Bio’s Global Marketing and Commercial teams, Business Development, Sales Operations, Field Applications, and Customer Support. Prior to Mission Bio, Roman worked at Agena Bioscience, where he was EVP and General Manager and SVP and Chief Commercial Officer, leading Agena through significant growth and facilitating its sale to Mesa Laboratories.
Nuvalent, Inc.
Henry Pelish, Ph.D. has been promoted to Chief Scientific Officer for Nuvalent, Inc., where he will continue to oversee discovery and early-stage development activities. Dr. Pelish contributed to the creation of Nuvalent and joined as Biology lead in 2018, overseeing the discovery and early-stage development of zidesamtinib, NVL-655 and NVL-330 and ongoing research and discovery efforts.
Fortrea
Robert “Bobby” Parks has been appointed as chief accounting officer (CAO), at Fortrea, responsible for their accounting function, including financial reporting, risk, controls, and compliance in accordance with applicable standards, laws, and regulations. Parks brings three decades of experience to the role. Starting his career in public accounting at Ernst & Young LLP, he served clients in global and regulated industries, including defense and construction. He was Senior Vice President and Corporate Controller at Quintiles, now IQVIA, and CAO at Syneos, a leading biopharmaceutical solutions organization.
CureLab Oncology
CureLab Oncology has announced Dr. Aubrey C. Galloway as their chief medical officer. Dr. Galloway, a renowned cardiac surgeon and the Seymour Cohn Professor of Cardiothoracic Surgery at NYU Langone Health, brings extensive expertise in clinical trials, cardiovascular disease xresearch, and an understanding of host inflammatory mediators of a variety of inflammatory diseases to this new position at CureLab Oncology.
